Canaccord analyst John Newman provides positive perspective on Lipocine Inc (NASDAQ:LPCN), encouraged by the biotech firm’s lead oral testosterone product, LPCN-1111, a drug …
H.C.
Healthcare analysts are weighing in on biotech companies Galena Biopharma Inc (NASDAQ:GALE) and Lipocine Inc (NASDAQ:LPCN), as shares of both companies fell sharply today, reaching record …
Canaccord Genuity analyst Corey Davis initiated coverage on shares of Lipocine Inc (NASDAQ:LPCN) with a Buy rating and a price target of $15.00, which implies an upside …
